Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

» Details

Guru Trades

VHT Guru Trades in

Q4 2015

VHT Guru Trades in Q4 2015

Ken Fisher 1,808 sh (New)
» More
Q1 2016

VHT Guru Trades in Q1 2016

Ken Fisher Sold Out
» More
Q4 2016

VHT Guru Trades in Q4 2016

Manning & Napier Advisors, Inc 8,121 sh (New)
Wallace Weitz 2,076 sh (New)
» More

Ratios

vs
industry
vs
history
PE Ratio 21.64
VHT's PE Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. VHT: 21.64 )
Ranked among companies with meaningful PE Ratio only.
VHT' s PE Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 24.37
Current: 21.64
0
24.37
PE Ratio without NRI 21.64
VHT's PE Ratio without NRI is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. VHT: 21.64 )
Ranked among companies with meaningful PE Ratio without NRI only.
VHT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0  Med: 0 Max: 24.37
Current: 21.64
0
24.37
PB Ratio 3.45
VHT's PB Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. VHT: 3.45 )
Ranked among companies with meaningful PB Ratio only.
VHT' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.95
Current: 3.45
0
3.95

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.32
VHT's Dividend Yield % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. VHT: 1.32 )
Ranked among companies with meaningful Dividend Yield % only.
VHT' s Dividend Yield % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.87
Current: 1.32
0
1.87
5-Year Yield-on-Cost % 1.32
VHT's 5-Year Yield-on-Cost % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. VHT: 1.32 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
VHT' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.87
Current: 1.32
0
1.87

More Statistics

Short Percentage of Float0.00%
52-Week Range $120.56 - 141.36
Shares Outstanding (Mil)43,763,748.00
» More Articles for VHT

Headlines

Articles On GuruFocus.com
Harmony Gold's Strike Ends Mar 24 2017 
Abbott Sells More Mylan Holdings Mar 24 2017 
Chou Income Fund 4th Quarter Message to Shareholders Mar 24 2017 
Francis Chou Comments on Resolute Forest Products Mar 24 2017 
Francis Chou Comments on Sears Holdings Corp Mar 24 2017 
Francis Chou Comments on Valeant Mar 24 2017 
Francis Chou Comments on EXCO Resources Mar 24 2017 
Learning From the Best: Keep Emotion Out of It Mar 24 2017 
Del Taco Looks Tasty Mar 24 2017 
The Behavior of Stock Market Manias Mar 24 2017 

More From Other Websites
Trump, Biogen and Amgen Hammer Healthcare ETFs Mar 20 2017
A Cost-Efficient Avenue to Health Care Exposure Mar 16 2017
David Tepper on Allergan: Does It Look Cheap? Mar 15 2017
What Wall Street Thinks Of The New Healthcare Reform Bill Mar 07 2017
Who Is Incyte Collaborating With? Mar 01 2017
How Gilead’s HIV Drugs Portfolio Fared in 2016 Mar 01 2017
Eli Lilly & Co.’s Valuation after Its 4Q16 Earnings Report Feb 28 2017
Pfizer’s Major Product Developments in 4Q16 Feb 28 2017
Eli Lilly and Co.’s New Products Portfolio Feb 27 2017
Pfizer’s Innovative Health and Essential Health in 4Q16 Feb 27 2017
Goldman Sachs and the Proposed Repeal of Obamacare Feb 21 2017
Pulling Back the Curtain on Danaher’s 4Q16 Operating Performance Feb 02 2017
Gilead Sciences Initiated Phase 3 Trials to Evaluate Filgotinib Feb 01 2017
Merck & Co.’s 4Q16 Estimates: Expect Flat Revenues Jan 31 2017
What Recent Developments Could Drive Eli Lilly’s Growth? Jan 27 2017
3 ETFs to Buy If You're Impressed With Johnson & Johnson's Fourth Quarter Jan 24 2017
Exploring Bristol-Myers Squibb’s Oncology Segment in 4Q16 Jan 24 2017
Why health-care stocks aren’t moving after President Trump’s Obamacare executive order Jan 24 2017
Can Q4 Earnings Revitalize Healthcare ETFs? Jan 23 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK